In the US, Kadcyla (ado-trastuzumab emtansine systemic) is a member of the drug class HER2 inhibitors and is used to treat Breast Cancer and Breast Cancer - Metastatic.
Ingredient matches for Kadcyla
Trastuzumab is reported as an ingredient of Kadcyla in the following countries:
- Bosnia & Herzegowina
- Croatia (Hrvatska)
Trastuzumab emtansine (a derivative of Trastuzumab) is reported as an ingredient of Kadcyla in the following countries:
- Hong Kong
- New Zealand
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.